While ABT-199 (venetoclax) has demonstrated remarkable efficacy in CLL treatment (Lasica and Anderson, 2021), its therapeutic impact is often compromised by the overexpression of BCL-2 and other anti-apoptotic proteins such as MCL-1. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.